Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/05/18 | $30,500,000 | Series B |
Longitude Capital Malin Corporation Tavistock Group Vivo Capital | undisclosed |
| 04/22/19 | $142,000,000 | Series C |
Aisling Capital Boxer Capital Longitude Capital Malin Corporation Novartis Venture Funds Pentwater Capital Management Perceptive Advisors Vivo Capital | undisclosed |
| 06/25/20 | $110,000,000 | Series D |
Adage Capital Management Fidelity Management & Research Company Schonfeld Strategic Advisors | undisclosed |
